Ferozsons Laboratories Eyes Acquisition of Barrett Hodgson Pakistan

Ferozsons Laboratories Limited (FEROZ) is exploring the potential acquisition of Barrett Hodgson Pakistan Pvt. Limited, a pharmaceutical firm, through a partnership with a consortium of prominent Pakistani business entities.

The publicly listed company communicated this development in an official notification to the Pakistan Stock Exchange (PSX) on Monday.

“During their urgent board meeting on May 17, 2025, the Board of Directors (BoD) assessed the proposal put forth by the investment committee concerning the possible acquisition of Barrett Hodgson Pakistan Pvt. Limited, in collaboration with a consortium of Pakistan’s leading business groups,” the notice stated.

According to the notification, the BoD has authorized the Chief Executive Officer and the Chief Financial Officer to conduct thorough due diligence, engage advisors, execute all relevant documentation, and undertake all necessary actions, including providing bid funds and security, related to the potential acquisition.

“The ultimate purchase price and equity investment will be subject to BoD approval, contingent upon the results of due diligence and other pertinent factors, including requisite approvals,” FEROZ clarified.

As indicated on the Barrett Hodgson Pakistan (BHP) website, the company is recognized as one of the top 15 pharmaceutical companies operating in Pakistan. The company states, “We serve nearly all medicinal categories and specializations by providing quality products at reasonable prices, maintaining a presence in the healthcare sector with a comprehensive range of over 100 brands and 240 formulations.”

Ferozsons Laboratories Limited, initially established in Pakistan in 1954 as a public limited company and later converted in 1960, specializes in the manufacturing, importing, and selling of pharmaceutical products and medical devices.

At the time of this report, FEROZ’s share price was Rs294.50, reflecting an increase of Rs15.22, or 5.45%.